Avasimibe


CAS No. : 166518-60-1

(Synonyms: CI-1011; PD-148515)

166518-60-1
Price and Availability of CAS No. : 166518-60-1
Size Price Stock
5mg $35 In-stock
10mg $55 In-stock
25mg $120 In-stock
50mg $198 In-stock
100mg $352 In-stock
200mg $572 In-stock
500 mg Get quote
1 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-13215
M.Wt: 501.72
Formula: C29H43NO4S
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 166518-60-1 :

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2]. IC50 & Target: IC50: 24 μM (ACAT1)[1].
IC50: 9.2 μM (ACAT2)[1] In Vitro: Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 µM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells[2].
Avasimibe (10 and 20 µM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT)[2].
Avasimibe (10 and 20 µM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells[2].
Avasimibe (10 and 20 µM) inhibits the metastasis of PCa cells[2]. In Vivo: Avasimibe (30 mg/kg, intraperitoneally injected on alternate days for 7 weeks) suppresses PCa cell growth and metastasis in vivo. Avasimibe has good biocompatibility and low toxicity[2].

Your information is safe with us.